Development and Evaluation of [ 68 Ga]Ga-Labeled Riboflavin Derivative for RFVT3-Targeted PET Imaging of Melanoma in Mice
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Yuanyuan Liang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory Sc…. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Positron-Emission Tomography, Riboflavin, Melanoma, Experimental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Fudan University, China Postdoctoral Science Foundation, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
The limited progress in treatment options and the alarming survival rates in advanced melanoma emphasize the significant research importance of early melanoma diagnosis. RFVT3, a crucial protein at the core of energy metabolism reprogramming in melanoma, might play a pivotal role in early detection. In this study, [68Ga]Ga-NOTA-RF, based on riboflavin (RF), was rationally developed and validated, serving as an innovative tool for positron emission tomography (PET) imaging of RFVT3 expression in melanoma. The in vitro assays of RFVT3 specificity of [68Ga]Ga-NOTA-RF were performed on B16F10 melanoma cells. Then, PET imaging of melanoma was investigated in B16F10 allograft mouse models with varying volumes. Biodistribution studies are used to clarify the behavior of [68Ga]Ga-NOTA-RF in vivo. [68Ga]Ga-NOTA-RF was obtained with high radiochemical purity (>95%). A significant uptake (37.79 ± 6.86%, n = 4) of [68Ga]Ga-NOTA-RF was observed over time in B16F10 melanoma cells, which was significantly inhibited by RFVT3 inhibitors RF or methylene blue (MB), demonstrating the specific binding of [68Ga]Ga-NOTA-RF. At 60 min postinjection, the tumor-to-muscle (T/M) ratio of [68Ga]Ga-NOTA-RF was 4.03 ± 0.34, higher than that of the RF-blocked group (2.63 ± 0.19) and MB-blocked group (2.14 ± 0.20). The T/M ratios for three distinct tumor volumes-small (5 mm), medium (10 mm), and large (15 mm) were observed to be 5.25 ± 0.28, 4.03 ± 0.34, and 3.19 ± 0.55, respectively. The expression of RFVT3 was validated by immunohistochemical staining in various tumor models, with small B16F10 tumors exhibiting the highest expression. [68Ga]Ga-NOTA-RF demonstrates promising properties for the early diagnosis of melanoma and the examination of minute metastatic lesions, indicating its potential to assist in guiding clinical treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd,…
- Theranostics and Translational Research Center, Institute of Clinical Medicine & Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Colleg…
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
ORCID-Profile: Xianzhong Zhang
Förderung
- Fudan University
- China Postdoctoral Science Foundation
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- National Isotope Engineering Technology Research Center
- National High-Level Hospital Clinical Research Funding
Zitieren
APA
Liang, Y., Wang, X., Chen, Y., Zeng, X., Liu, J., Zhao, Z., Yang, H., Zhang, Q., Li, J., Guo, Z., & Zhang, X. (2024). Development and Evaluation of [ 68 Ga]Ga-Labeled Riboflavin Derivative for RFVT3-Targeted PET Imaging of Melanoma in Mice. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00209
Vancouver
Liang Y, Wang X, Chen Y, Zeng X, Liu J, Zhao Z, et al. Development and Evaluation of [ 68 Ga]Ga-Labeled Riboflavin Derivative for RFVT3-Targeted PET Imaging of Melanoma in Mice. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00209
BibTeX
@article{Liang2024,
author = {Liang, Yuanyuan and Wang, Xueqi and Chen, Yingxi and Zeng, Xinying and Liu, Jia and Zhao, Zuoquan and Yang, Hongzhang and Zhang, Qinglin and Li, Jindian and Guo, Zhide and Zhang, Xianzhong},
title = {Development and Evaluation of [ 68 Ga]Ga-Labeled Riboflavin Derivative for RFVT3-Targeted PET Imaging of Melanoma in Mice},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00209}
}
EUVIMED